BioPharma Dive January 16, 2019
Andrew Dunn

Dive Brief:

  • Aiming to keep pace with the acceleration of cell and gene therapy research, the Food and Drug Administration plans to expand its clinical review staff, release a series of wide-ranging guidance documents and crack down on bad actors, two agency leaders said in a statement released Tuesday.
  • FDA Commissioner Scott Gottlieb and Peter Marks, director of the Center for Biologics Evaluation and Research, said in a joint statement they anticipate more than 200 Investigational New Drug applications per year by 2020 for cell and gene therapeutic candidates, adding to a current total of more than 800 such filings. That will help lead to, they predict, 10 to 20 approvals each year for these treatments by 2025.
  • ...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Precision Medicine, Regulations, Technology
FDA approves Lumicell’s breast cancer imaging tool
Boehringer Ingelheim Strikes Regenerative Med R&D Deal Spanning MASH & More Liver Diseases
Opinion: An FDA pathway can accelerate innovation for Duchenne muscular dystrophy
What principles should guide artificial intelligence innovation in healthcare?
Roche Drug Scores Label Expansion for Earlier Use in Lung Cancer

Share This Article